10-Q · May 6, 2026
Royalty Pharma plc reported a first-quarter 2026 net income of $294.7 million, up 23.1% year-over-year, and total operating revenue of $630.6 million, reflecting an 11% increase compared to the previous year. EBITDA…
Earnings analysis · 10-Q
RPRX earnings analysis
Filed November 4, 2026 · Our reading of the company's report
The latest report
The accompanying earnings analysis indicates a strong third quarter, with $890 million of Portfolio Receipts exceeding the $883.1 million consensus estimate, 9% Royalty Receipts growth to $883 million and $686 million…
Read full summary
The accompanying earnings analysis indicates a strong third quarter, with $890 million of Portfolio Receipts exceeding the $883.1 million consensus estimate, 9% Royalty Receipts growth to $883 million and $686 million of operating cash flow. Full-year 2026 Portfolio Receipts guidance was raised to $3.50 billion-$3.55 billion, although the company continues to face a $150 million pelacarsen impairment, substantial leverage of $8.8 billion in senior unsecured notes and concentration in its top five franchises, which represented 59% of first-nine-month Royalty Receipts. The filing also highlights a potentially material Vertex/Alyftrek royalty dispute and expanded cybersecurity and AI-related risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Portfolio Receipts beat consensus
The accompanying quarterly earnings analysis reports $890 million of third-quarter Portfolio Receipts, ahead of the $883.1 million consensus estimate. Royalty Receipts increased 9% to $883 million.
-
Raised full-year outlook
Full-year 2026 Portfolio Receipts guidance was raised to $3.50 billion-$3.55 billion from $3.40 billion-$3.50 billion, while operating and professional costs guidance was reduced to 5.5%-6.0% of Portfolio Receipts from 5.5%-6.5%.
-
Strong operating cash generation
The accompanying earnings analysis reports $686 million of operating cash flow for the quarter, supporting liquidity despite a $150 million pelacarsen impairment charge.
-
Continued share repurchases
Royalty Pharma repurchased 1.471 million Class A ordinary shares during the third quarter at an average price of $59.25 per share. The remaining authorization was $1.600 billion at September 30, 2026.
-
Controls remained effective
The filing states that disclosure controls were effective at the reasonable assurance level as of the quarter-end and that there were no changes in internal control that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
High leverage and liquidity exposure
As of September 30, 2026, senior unsecured notes totaled $8.8 billion and the company had up to $1.8 billion of available revolving commitments. The filing warns that cash flow may be insufficient to service debt or meet other liquidity needs.
-
Royalty concentration
The top five product franchises accounted for 59% of Royalty Receipts in the first nine months of 2026, creating material concentration risk if one or more major products deteriorate.
-
Vertex royalty dispute
The company states that, beginning in the second quarter of 2025, it did not receive the full amount of royalty receipts it believes it was contractually owed from Vertex on Alyftrek net sales and has commenced dispute-resolution procedures. Any recovery will be recognized only upon a favorable resolution.
-
Expanded AI and cyber risk
The risk-factor discussion now expressly identifies artificial-intelligence risks, including flawed algorithms, biased or insufficient data, unclear intellectual-property rights and potential legal or reputational harm. The filing states that the company has been subject to cybersecurity vulnerabilities in the past and expects to face them in the future.
-
Product and royalty-duration risk
The filing states that a shortening of royalty terms could reduce royalty receipts, lower effective interest rates or result in permanent impairment. This is particularly relevant given the accompanying analysis's $150 million pelacarsen impairment charge.
Management's outlook
The supplied filing text does not include MD&A or a quantitative outlook. Per the accompanying prior analysis, full-year 2026 Portfolio Receipts guidance was raised to $3.50 billion-$3.55 billion from $3.40 billion-$3.50 billion, implying Royalty Receipts growth of 10%-11%; operating and professional costs guidance was reduced to 5.5%-6.0% of Portfolio Receipts from 5.5%-6.5%.
Earlier filings 4
10-K · February 11, 2026
Royalty Pharma (RPRX) positions itself as the largest buyer of biopharmaceutical royalties with scale, high cash conversion and a disciplined capital-allocation framework. In 2025 the company generated $3.3 billion of…
10-Q · May 8, 2025
Royalty Pharma reported Q1 2025 income and other revenues of $568,247,000 (vs $567,978,000 in Q1 2024) and generated operating income of $534,182,000 (versus an operating loss of $73,774,000 in Q1 2024). Diluted Class A…
10-K · February 12, 2025
Royalty Pharma (RPRX) positions itself as the largest buyer of biopharmaceutical royalties with a capital-efficient, high-cash-conversion model focused on long-duration royalty assets. In 2024 the company generated $2.8…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.